TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease In the dose-expansion cohort of a phase I/II study (ClinicalTrials.gov identifier: NCT03625037), adults with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results